Introduction
============

Gastric cancer (GC) is a widespread malignant tumor around the world with a high incidence.[@b1-ott-10-4795] Although we have made great progress in the treatment of GC, the prognosis after surgery still remains pessimistic. One important cause of the poor prognosis for GC patients is that most of them are diagnosed at an advanced stage with diffused filtration and lymph node metastasis, because there are no distinctive symptoms in early stage.[@b2-ott-10-4795],[@b3-ott-10-4795]

The age of GC patients is commonly 50--70 years, and the average onset age is \~60 years.[@b4-ott-10-4795],[@b5-ott-10-4795] However, younger (≤40 years) and older (≥70 years) GC patients still make up a biggish proportion of the total GC population.[@b6-ott-10-4795],[@b7-ott-10-4795] Age is an important factor affecting survival in patients with cancer,[@b8-ott-10-4795] and there have been many reports suggesting that young GC patients tend to have a better prognosis than middle-aged patients;[@b5-ott-10-4795],[@b6-ott-10-4795] however, the differences in both prognosis and clinicopathological features between younger and older patients still remain to be further discussed.

Because of these factors, we retrospectively studied 112 younger GC patients and 358 older GC patients who accepted gastrectomy in our hospital, and we aimed to compare the differences in clinicopathological features and prognoses between younger and older GC patients. Recently, studies have shown that preoperative inflammatory responses and nutritional status both play important roles in tumori-genesis, progression and prognosis in various cancers.[@b9-ott-10-4795],[@b10-ott-10-4795] The monocyte-to-lymphocyte ratio (MLR), a biomarker connected to a systemic inflammatory response, can reveal the immunity that hosts owned to show resistance to tumors.[@b11-ott-10-4795] We, therefore, analyzed the biomarker MLR and prognostic nutritional index (PNI) to compare the immunity and nutritional status of younger and older GC patients.

Patients and methods
====================

Patients and data
-----------------

The study was carried out at the Harbin Medical University Cancer Hospital. From January 2007 to December 2011, a consecutive total of 1,990 patients with 112 GC patients under 41 years old and 358 GC patients over 69 years old who underwent gastrectomies for GC were recruited for this study. The age composition of these patients is shown in [Figure 1](#f1-ott-10-4795){ref-type="fig"}. The inclusion criteria were as follows: all of the patients 1) had preoperative gastroscopies and pathological diagnoses of GC; 2) never received neoadjuvant chemotherapies, radiotherapies or other anticancer treatments; 3) underwent total or subtotal gastrectomies and radical surgery (R0) patients underwent D2+ lymph nodes resection, while R1 and R2 patients underwent regional lymph nodes resection. The stagings were based on the 7th edition of the TNM classification (for the "Tumor-Nodes-Metastases" system) by the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC).[@b12-ott-10-4795] Every patient was followed up regularly from the time of surgery until June 2016 or death (in the first two postoperative years it was every 3 months and in the following several years it was at 6-month intervals). This research had the support and approval of the Medical Ethics Committee of the Harbin Medical University Cancer Hospital, and all patients signed the informed consent for the use of their data for future study.

We recorded the age, gender, tumor depth (T), number of metastatic lymph nodes (N), distant metastasis (M), AJCC TNM stage, radicality, tumor size, tumor location, metastasis lymph node rate (MLNR), differentiation, ascites, carbohydrate antigen (CA) 19--9 (U/mL), carcinoembryonic antigen (CEA) (ng/mL), hemoglobin (Hb) (g/L), albumin count (g/L), lymphocyte count (10^9^/L) and monocyte count (10^9^/L). The average MLNR was 31.5%. CA19--9 exceeding 37 U/mL, CEA exceeding 5 ng/mL and Hb \<131 g/L were identified as positive. MLR was calculated as the monocyte count/lymphocyte count.[@b9-ott-10-4795] PNI was calculated as the albumin count + lymphocyte count ×5.[@b10-ott-10-4795]

Statistical analysis
--------------------

A chi-squared test was used to assess the significant differences in the clinicopathological features between younger and older GC patients. Survival curves were calculated with a Kaplan--Meier survival analysis, and the equivalences of survival curves were analyzed by using a log-rank test. Multivariate analyses were evaluated by the Cox proportional hazards model. A Student's *t*-test was used to compare the MLR, PNI, lymphocyte, monocyte and albumin between younger and older patients. A *P*\<0.05 was considered to be statistically significant. Data analysis was performed using SPSS 17.0.

Results
=======

The clinicopathological features of 112 younger GC patients and 358 older GC patients are shown in [Table 1](#t1-ott-10-4795){ref-type="table"}. There were more women in the younger GC patient group than in the older GC patient group (47.3% vs 23.5%, *P*\<0.001). The proportion of undifferentiated adenocarcinomas in younger GC patients was significantly higher than that in older GC patients (94.6% vs 76.8%, *P*\<0.001). The positive rates of CA19--9 and CEA in younger GC patients were significantly lower than those in older GC patients (14.3% vs 24.0%, 9.8% vs 25.1%, *P*~all~\<0.05). However, for other features, such as tumor depth, number of metastatic lymph nodes, distant metastasis, AJCC TNM stage, surgical radicality, tumor size, tumor location, MLNR, ascites and Hb, there were no significant differences between younger and older GC patients.

In the Kaplan--Meier survival analyses, the overall survival times of the 112 younger GC patients were much better than those of the 358 older GC patients ([Figure 2](#f2-ott-10-4795){ref-type="fig"}, *P*\<0.001). Younger patients had a much better prognosis than older patients in the stages II (*P*=0.013) and III (*P*\<0.001), but this was not the case in the stages I (*P*=0.207) and IV (*P*=0.069).

We used univariate and multivariate analyses to assess the risk parameters for prognoses in the 470 GC patients ([Table 2](#t2-ott-10-4795){ref-type="table"}). The results showed that the age, tumor depth, number of metastatic lymph nodes, distant metastasis, AJCC TNM stage, surgical radicality, tumor size, MLNR, CA19--9 and CEA were all significantly associated with the prognosis in univariate analyses. However, in the multivariate analysis, only age, number of metastatic lymph nodes, AJCC TNM stage, surgical radicality and tumor size were independent risk parameters. Then, we independently analyzed the risk parameters for the prognosis in the 112 younger patients and 358 older patients. In the 112 younger patients, tumor depth, number of metastatic lymph nodes, distant metastasis, AJCC TNM stage, radicality, tumor size and MLNR were all associated with overall survival in univariate analyses, but only the number of metastatic lymph nodes was an independent risk parameter for overall survival ([Table 3](#t3-ott-10-4795){ref-type="table"}). In the 358 older GC patients, tumor depth, number of metastatic lymph nodes, distant metastasis, AJCC TNM stage, radicality, tumor size, MLNR, differentiation, ascites, CA19--9 and Hb were associated with overall survival in univariate analyses, and only the AJCC TNM stage, surgical radicality and tumor size were independent risk parameters for overall survival ([Table 4](#t4-ott-10-4795){ref-type="table"}).

Additionally, we conducted the survival analysis of MLR and PNI in younger and older GC patients, respectively. The cutoff value of MLR was the mean value that was 0.240 in younger GC patients and 0.292 in older GC patients, and so was the PNI that was 52.883 in younger GC patients and 48.862 in older GC patients. We found that both younger GC patients with lower MLR and older GC patients with higher PNI had much better prognoses ([Figure 3](#f3-ott-10-4795){ref-type="fig"}). Comparing the MLR and PNI values between younger and older GC patients, we found that MLR in younger patients was significantly lower (*P*=0.011) and PNI was significantly higher (*P*\<0.001) than those in older patients ([Table 5](#t5-ott-10-4795){ref-type="table"}). The divergence of MLR was not significant when it was divided into stages I, II, III and IV between younger and older GC patients, while it was significant of PNI in stages II, III and IV (*P*~all~\<0.05), but not in stage I. Tavares et al reported that lymphocyte may decline accompanied with an increase in age.[@b13-ott-10-4795] So we calculated the differences of lymphocyte, monocyte and albumin in the two groups. We found that only albumin was significantly different between younger and older GC patients (*P*\<0.001). Finally, we compared the albumin between the two groups in different stages and found that the differences were statistically significant in stages II, III and IV (*P*~all~\<0.05), but not in stage I (*P*=0.371).

Discussion
==========

It is generally believed that GC is an age-related disease, and in recent decades, the number of younger and older GC patients has been increasing. It is necessary to clarify the adverse prognostic factors for patients in different age groups. In our study, we found that gender, differentiation, and CA19--9 and CEA were significantly different among younger and older GC patients. There were more women in the younger group, and the reason for this phenomenon remains unclear. There have been reports that estrogen can promote the diffusion and inhibit apoptosis in several cancers,[@b14-ott-10-4795]--[@b16-ott-10-4795] and some have considered that this phenomenon may be related with their recent pregnancies.[@b17-ott-10-4795],[@b18-ott-10-4795] Jaspers et al suggested that there were more estrogen receptors in younger patients;[@b19-ott-10-4795] however, another report demonstrated that only the number of metastatic lymph nodes was associated with estrogen receptor expression rather than other factors such as gender, age and tumor size.[@b20-ott-10-4795] Younger GC patients generally had poor differentiation and this may be owing to that younger patients had higher infection rates of *Helicobacter pylori*, which lead to poor differentiation.[@b21-ott-10-4795],[@b22-ott-10-4795] Some reports have suggested that undifferentiated GC cells originated from gastric fundic glands, while intestinal metaplasia usually led to differentiated gastric adenocarcinoma.[@b3-ott-10-4795],[@b23-ott-10-4795] Higher CEA and CA19--9 levels in older patients have also been reported.[@b24-ott-10-4795],[@b25-ott-10-4795]

In the multivariate analysis of the 470 patients, age, number of metastatic lymph nodes, AJCC TNM stage, radicality and tumor size were independent risk factors. Our study showed that younger patients had a much better prognosis than older patients, but in another study, Yukiko reported that the survival rate of young patients (\<40) with GC was the same as that of patients in their 60s.[@b5-ott-10-4795] This result may be due to the different cohorts we analyzed. In the 112 younger GC patients, only the number of metastatic lymph nodes was an independent risk parameter according to the multivariate analysis. Yukiko also reported that younger GC patients usually have metastasis to lymph nodes.[@b5-ott-10-4795] It is believed that undifferentiated adenocarcinomas tend to have vertical infiltration, which leads to lymph node metastasis.[@b21-ott-10-4795]

Younger GC patients have worse prognoses in general; however, in this study, we found that younger patients had a much better overall survival rate than older patients. Although we failed to show the significant prognostic differences between younger and older patients in stage I and stage IV, it may be because the patients in stage I and stage IV were too few. The difference of MLR and PNI between younger and older patients indicated that younger patients possessed better immunity and nutritional status, which may be the main reason for their longer overall survival. And the better nutritional status may play a more important role. However, more investigations are needed to explain this phenomenon. We hesitate if strengthening nutrition for older GC patients after operation could improve prognosis. This drives us to pay more attention to the nutritional problems of the elder GC patients.

There were some limitations in this study. First, this was a retrospective investigation based on a single hospital, and this may have led to some error. Second, not all of the patients who had gastrectomy in our hospital had successful consequence follow-up, which led to a smaller cohort. Third, it may be the most important that although we had told all of these patients who needed adjuvant chemotherapies to undergo subsequent treatments in our hospital or other hospitals, not all of them come back for subsequent standard treatments. So we cannot get this part of the data and recruit this diathesis into consideration. We have to say that this is really a pity.

Conclusion
==========

Younger and older GC patients had significant differences in clinicopathological features, and younger GC patients had much better overall survival, lower MLR and higher PNI than older GC patients. The number of metastatic lymph nodes was the only risk parameter for a prognosis in younger GC patients, and AJCC TNM stage, radicality and tumor size were independent risk parameters for a prognosis in older GC patients. We should take more effective treatments for younger GC patients with lymph nodes metastasis and pay more attention to the nutritional problems of older GC patients.
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![Age composition of 1,990 GC patients.\
**Abbreviation:** GC, gastric cancer.](ott-10-4795Fig1){#f1-ott-10-4795}

![Comparison of overall survival between younger and older gastric cancer patients.\
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![Survival analysis of MLR and PNI in younger and older gastric cancer patients.\
**Abbreviations:** Cum, cumulative; MLR, monocyte-to-lymphocyte ratio; PNI, prognostic nutritional index.](ott-10-4795Fig3){#f3-ott-10-4795}

###### 

Clinicopathological features of younger and older GC patients

  -----------------------------------------------------------------------------------------------------------
  Factors                                                      Younger\     Older\       *χ^2^*   *P*-value
                                                               (n=112)      (n=358)               
  ------------------------------------------------------------ ------------ ------------ -------- -----------
  Gender                                                                                 23.512   \<0.001

   Male                                                        59 (52.7)    274 (76.5)            

   Female                                                      53 (47.3)    84 (23.5)             

  Tumor depth                                                                            0.757    0.86

   T1                                                          7 (6.3)      17 (4.7)              

   T2                                                          6 (5.3)      25 (7.0)              

   T3                                                          33 (29.5)    102 (28.5)            

   T4                                                          66 (58.9)    214 (59.8)            

  Lymph nodes                                                                            6.153    0.104

   N0                                                          20 (17.9)    93 (26.0)             

   N1                                                          27 (24.1)    61 (17.0)             

   N2                                                          24 (21.4)    93 (26.0)             

   N3                                                          41 (36.6)    111 (31.0)            

  Distant metastasis                                                                     2.42     0.085

   M0                                                          94 (83.9)    320 (89.4)            

   M1                                                          18 (16.1)    38 (10.6)             

  AJCC stage                                                                             3.463    0.326

   I                                                           5 (4.5)      25 (7.0)              

   II                                                          30 (26.8)    89 (24.9)             

   III                                                         59 (52.7)    206 (57.5)            

   IV                                                          18 (16.0)    38 (10.6)             

  Radicality                                                                             0.466    0.495

   R0                                                          85 (75.9)    260 (72.6)            

   R1 or R2                                                    27 (24.1)    98 (27.4)             

  Tumor size (cm)                                                                        0.687    0.407

   ≤6                                                          70 (62.5)    239 (66.8)            

   \>6                                                         42 (37.5)    119 (33.2)            

  Tumor location                                                                         6.365    0.095

   Upper                                                       12 (10.7)    61 (17.0)             

   Middle                                                      21 (18.8)    64 (17.9)             

   Low                                                         64 (57.1)    208 (58.1)            

   Whole                                                       15 (13.4)    25 (7.0)              

  MLNR                                                                                   0.022    0.912

   ≤31.5%                                                      67 (59.8)    217 (60.6)            

   \>31.5%                                                     45 (40.2)    141 (39.4)            

  Differentiation[a](#tfn1-ott-10-4795){ref-type="table-fn"}                             17.662   \<0.001

   Differentiated                                              6 (5.4)      83 (23.2)             

   Undifferentiated                                            106 (94.6)   275 (76.8)            

  Ascites                                                                                2.338    0.156

   No                                                          105 (93.8)   347 (96.9)            

   Yes                                                         7 (6.2)      11 (3.1)              

  CA19--9 (U/mL)                                                                         4.76     0.029

   Negative                                                    96 (85.7)    272 (76.0)            

   Positive                                                    16 (14.3)    86 (24.0)             

  CEA (ng/mL)                                                                            11.865   0.001

   Negative                                                    101 (90.2)   268 (74.9)            

   Positive                                                    11 (9.8)     90 (25.1)             

  Hb (g/L)                                                                               1.61     0.204

   Positive                                                    60 (53.6)    216 (60.3)            

   Negative                                                    52 (46.4)    142 (39.7)            
  -----------------------------------------------------------------------------------------------------------

**Note:**

Grades 1 and 2 were differentiated, and grades 3 and 4 were undifferentiated.

**Abbreviations:** AJCC, American Joint Committee on Cancer; CA, carbohydrate antigen; CEA, carcinoembryonic antigen; GC, gastric cancer; Hb, hemoglobin; MLNR, metastasis lymph node rate.

###### 

Survival analysis of the 470 younger and older GC patients

  Parameter                                           Univariate analysis   Multivariate analysis                                              
  --------------------------------------------------- --------------------- ----------------------- --------- -------- ----------------------- ---------
  Age (younger/older)                                 0.513                 1.671 (1.296--2.153)    \<0.001   0.598    1.818 (1.383--2.391)    \<0.001
  Gender (male/female)                                −0.170                0.843 (0.675--1.054)    0.134     −0.020   0.980 (0.766--1.255)    0.876
  Tumor depth (T1/T2/T3/T4)                           0.372                 1.451 (1.282--1.643)    \<0.001   −0.021   0.979 (0.810--1.183)    0.825
  Lymph nodes (N0/N1/N2/N3)                           0.495                 1.640 (1.493--1.801)    \<0.001   0.213    1.237 (1.029--1.4870)   0.024
  Distant metastasis (M0/M1)                          1.492                 4.447 (3.216--6.150)    \<0.001   0.458    1.581 (0.930--2.689)    0.091
  AJCC stage (I/II/III/IV)                            0.915                 2.497 (2.131--2.927)    \<0.001   0.394    1.483 (1.032--2.131)    0.033
  Radicality (R0/R1 or R2)                            1.179                 3.252 (2.564--4.126)    \<0.001   0.484    1.622 (1.211--2.174)    0.001
  Tumor size (≤6 cm/\>6 cm)                           0.794                 2.212 (1.786--2.740)    \<0.001   0.452    1.572 (1.237--1.999)    \<0.001
  Tumor location (upper/middle/low/whole)             −0.052                0.950 (0.836--1.078)    0.424     −0.047   0.954 (0.843--1.081)    0.461
  MLNR (≤31.5%/\>31.5%)                               1.049                 2.856 (2.298--3.549)    \<0.001   0.304    1.355 (0.978--1.877)    0.068
  Differentiation (differentiated/undifferentiated)   0.177                 1.194 (0.935--1.524)    0.156     0.012    1.012 (0.780--1.314)    0.929
  Ascites (no/yes)                                    0.382                 1.466 (0.857--2.506)    0.162     −0.219   0.803 (0.451--1.430)    0.456
  CA19--9 (negative/positive)                         0.364                 1.439 (1.136--1.823)    0.003     −0.007   0.993 (0.771--1.279)    0.958
  CEA (negative/positive)                             0.346                 1.423 (1.114--1.792)    0.004     0.125    1.133 (0.877--1.462)    0.339
  Hb (≤130/\>130) (g/L)                               −0.168                0.846 (0.691--1.035)    0.104     −0.156   0.855 (0.687--1.065)    0.163

**Abbreviations:** AJCC, American Joint Committee on Cancer; CA, carbohydrate antigen; CEA, carcinoembryonic antigen; CI, confidence interval; GC, gastric cancer; Hb, hemoglobin; HR, hazards ratio; MLNR, metastasis lymph node rate.

###### 

Survival analysis of the 112 younger GC patients

  Parameter                                           Univariate analysis   Multivariate analysis                                              
  --------------------------------------------------- --------------------- ----------------------- --------- -------- ----------------------- -------
  Gender (male/female)                                −0.192                0.825 (0.521--1.307)    0.413     0        1.000 (0.573--1.746)    0.999
  Tumor depth (T1/T2/T3/T4)                           0.415                 1.514 (1.142--2.008)    0.004     0.287    1.333 (0.820--2.165)    0.246
  Lymph nodes (N0/N1/N2/N3)                           0.636                 1.890 (1.465--2.438)    \<0.001   0.536    1.710 (1.007--2.903)    0.047
  Distant metastasis (M0/M1)                          1.524                 4.590 (2.266--9.297)    \<0.001   1.119    3.063 (0.632--14.836)   0.164
  AJCC stage (I/II/III/IV)                            0.966                 2.629 (1.799--3.842)    \<0.001   −0.198   0.821 (0.278--2.421)    0.720
  Radicality (R0/R1 or R2)                            1.502                 4.492 (2.364--8.538)    \<0.001   0.597    1.816 (0.683--4.830)    0.232
  Tumor size (≤6 cm/\>6 cm)                           0.725                 2.065 (1.266--3.367)    0.004     0.415    1.515 (0.838--2.740)    0.169
  Tumor location (upper/middle/low/whole)             0.010                 1.010 (0.727--1.403)    0.952     −0.129   0.879 (0.629--1.228)    0.450
  MLNR (≤31.5%/\>31.5%)                               1.163                 3.199 (1.941--5.274)    \<0.001   0.154    1.166 (0.507--2.680)    0.718
  Differentiation (differentiated/undifferentiated)   0.244                 1.276 (0.464--3.508)    0.637     −0.052   0.950 (0.286--3.148)    0.933
  Ascites (no/yes)                                    0.146                 1.157 (0.415--3.231)    0.780     −1.088   0.337 (0.071--1.608)    0.173
  CA19--9 (negative/positive)                         0.140                 1.150 (0.601--2.200)    0.673     0.035    1.036 (0.496--2.162)    0.926
  CEA (negative/positive)                             0.611                 1.843 (0.938--3.622)    0.076     0.628    1.873 (0.680--5.164)    0.225
  Hb (negative/positive)                              0.444                 1.558 (0.964--2.518)    0.070     0.364    1.439 (0.829--2.497)    0.196

**Abbreviations:** AJCC, American Joint Committee on Cancer; CA, carbohydrate antigen; CEA, carcinoembryonic antigen; CI, confidence interval; GC, gastric cancer; Hb, hemoglobin; HR, hazards ratio; MLNR, metastasis lymph node rate.

###### 

Survival analysis of the 358 older GC patients

  Parameter                                           Univariate analysis   Multivariate analysis                                              
  --------------------------------------------------- --------------------- ----------------------- --------- -------- ----------------------- -------
  Gender (male/female)                                −0.003                0.997 (0.767--1.295)    0.980     0.031    1.032 (0.780--1.365)    0.826
  Tumor depth (T1/T2/T3/T4)                           0.360                 1.433 (1.247--1.648)    \<0.001   −0.110   0.896 (0.722--1.112)    0.319
  Lymph nodes (N0/N1/N2/N3)                           0.492                 1.635 (1.479--1.807)    \<0.001   0.169    1.185 (0.965--1.453)    0.105
  Distant metastasis (M0/M1)                          1.563                 4.772 (3.306--6.888)    \<0.001   0.296    1.345 (0.745--2.426)    0.325
  AJCC stage (I/II/III/IV)                            0.950                 2.586 (2.167--3.087)    \<0.001   0.528    1.695 (1.141--2.517)    0.009
  Radicality (R0/R1 or R2)                            1.097                 2.995 (2.317--3.882)    \<0.001   0.467    1.595 (1.164--2.186)    0.004
  Tumor size (≤6 cm/\>6 cm)                           0.850                 2.339 (1.841--2.972)    \<0.001   0.481    1.618 (1.233--2.122)    0.001
  Tumor location (upper/middle/low/whole)             −0.046                0.955 (0.833--1.095)    0.510     −0.069   0.934 (0.811--1.075)    0.339
  MLNR (≤31.5%/\>31.5%)                               1.045                 2.842 (2.229--3.624)    \<0.001   0.291    1.337 (0.930--1.923)    0.116
  Differentiation (differentiated/undifferentiated)   0.311                 1.364 (1.055--1.765)    0.018     0.038    1.038 (0.791--1.364)    0.786
  Ascites (no/yes)                                    0.699                 2.012 (1.069--3.787)    0.030     0.091    1.095 (0.557--2.151)    0.792
  CA19--9 (negative/positive)                         0.367                 1.443 (1.116--1.867)    0.005     −0.009   0.991 (0.748--1.3130)   0.949
  CEA (negative/positive)                             0.225                 1.253 (0.969--1.619)    0.085     0.090    1.094 (0.834--1.436)    0.517
  Hb (negative/positive)                              −0.374                0.688 (0.547--0.865)    0.001     −0.270   0.764 (0.594--0.982)    0.035

**Abbreviations:** AJCC, American Joint Committee on Cancer; CA, carbohydrate antigen; CEA, carcinoembryonic antigen; CI, confidence interval; GC, gastric cancer; Hb, hemoglobin; HR, hazards ratio; MLNR, metastasis lymph node rate.

###### 

Comparison of MLR, PNI, lymphocyte, monocyte and albumin between younger and older GC patients

  Stage        Biomarker      Group          $\overline{x} \pm s$   *t*       *P*-value
  ------------ -------------- -------------- ---------------------- --------- -----------
  Stage I      MLR            Younger        0.220±0.051            −0.958    0.346
  Older        0.301±0.200                                                    
  PNI          Younger        55.250±4.226   1.071                  0.293     
  Older        51.340±7.860                                                   
  Albumin      Younger        45.100±4.009   0.909                  0.371     
  Older        42.390±6.364                                                   
  Stage II     MLR            Younger        0.210±0.093            −1.909    0.059
  Older        0.290±0.206                                                    
  PNI          Younger        55.890±6.413   4.00                   \<0.001   
  Older        49.330±8.156                                                   
  Albumin      Younger        46.050±4.974   4.228                  \<0.001   
  Older        40.310±6.838                                                   
  Stage III    MLR            Younger        0.240±0.110            −1.453    0.147
  Older        0.270±0.178                                                    
  PNI          Younger        51.500±7.369   2.201                  0.029     
  Older        49.000±7.760                                                   
  Albumin      Younger        42.090±6.032   2.423                  0.016     
  Older        39.850±6.317                                                   
  Stage IV     MLR            Younger        0.300±0.191            −1.374    0.175
  Older        0.400±0.269                                                    
  PNI          Younger        51.760±6.901   2.711                  0.009     
  Older        45.350±8.803                                                   
  Albumin      Younger        43.390±5.820   2.678                  0.010     
  Older        38.230±7.115                                                   
  All stages   MLR            Younger        0.240±0.123            −2.569    0.011
  Older        0.292±0.201                                                    
  PNI          Younger        52.883±7.140   4.730                  \<0.001   
  Older        48.862±8.060                                                   
  Lymphocyte   Younger        1.880±0.716    1.241                  0.215     
  Older        1.780±0.751                                                    
  Monocyte     Younger        0.410±0.155    −1.649                 0.100     
  Older        0.440±0.174                                                    
  Albumin      Younger        43.490±5.845   5.078                  \<0.001   
  Older        39.970±6.571                                                   

**Abbreviations:** GC, gastric cancer; MLR, monocyte-to-lymphocyte ratio; PNI, prognostic nutritional index.
